Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and... see more

Recent & Breaking News (TSX:MSCL)

Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247

Business Wire 16 hours ago

Satellos Announces Participation in September 2024 Investor Conferences

Business Wire 13 days ago

Satellos Biosciences to advance DMD treatment to clinical trials

Jocelyn Aspa August 19, 2024

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Business Wire August 19, 2024

Satellos Announces Q2 2024 Financial Results and Updated Canine Data

Business Wire August 12, 2024

Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

Business Wire August 8, 2024

Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Business Wire July 11, 2024

Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy ("DMD")

Business Wire July 2, 2024

Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference

Business Wire June 27, 2024

Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy

Business Wire May 28, 2024

Satellos Bioscience Inc. Opens the Market

PR Newswire May 15, 2024

Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders

Business Wire May 14, 2024

Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights

Business Wire May 14, 2024

Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Business Wire April 8, 2024

Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights

Business Wire March 27, 2024

Satellos to Present at Upcoming Virtual Investor Conferences in March and April

Business Wire March 14, 2024

Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024

Business Wire March 5, 2024

Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference

Business Wire March 4, 2024

Satellos Recognized as a Top 50 TSX Venture Exchange Company

Business Wire February 21, 2024

Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Business Wire February 20, 2024